Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioStratum, CRN Spar Over Pyridoxamine’s Pre-DSHEA Marketing Status

This article was originally published in The Tan Sheet

Executive Summary

BioStratum insists there is no evidence supporting the Council for Responsible Nutrition's claim that pyridoxamine was sold as a dietary ingredient before 1994 and says the ingredient should not be considered "grandfathered" under DSHEA

You may also be interested in...



FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision

Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition

Related Content

Topics

UsernamePublicRestriction

Register

PS098747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel